Crossmark

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Crossref DOI link: https://doi.org/10.1186/s12885-019-5674-5

Published Online: 2019-06-13

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schwartzberg, Lee http://orcid.org/0000-0002-7433-3428
McIntyre, Kristi

Wilks, Sharon

Puhalla, Shannon

O’Shaughnessy, Joyce

Berrak, Erhan

He, Yaohua

Vahdat, Linda
Funding

Funding for this research was provided by:

Eisai Inc.
License Information

Text and Data Mining valid from 2019-06-13

Version of Record valid from 2019-06-13
More Information

Article History

Received: 21 November 2017

Accepted: 3 May 2019

First Online: 13 June 2019

Ethics approval and consent to participate

: Both studies were conducted in accordance with the Declaration of Helsinki (2008), and the protocol and informed consent forms were submitted for approval to institutional review boards. All patients provided written informed consent prior to any study-related procedures. A complete list of participating trial sites and institutional review boards is provided as an additional file.

: Not applicable.

: LS is a consultant/adviser for and has received funding from Eisai Inc., and Helsinn.KM has no conflict of interest to disclose.SW has no conflict of interest to disclose.SP is a consultant for Celldex, MedImmune, Pfizer, AbbVie, AstraZeneca, Eisai, and Puma.JO is a consultant/adviser for Eisai Inc.EB and YH are former employees of Eisai Inc.LV is a consultant/adviser for Eisai Inc., Bristol-Myers Squibb Oncology, and Berg Pharma.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below